Singapore markets close in 27 minutes

Tarsus Pharmaceuticals, Inc. (TARS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.35-0.68 (-1.79%)
At close: 04:00PM EDT
42.18 +4.83 (+12.93%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.41B
Enterprise value 1.21B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)62.90
Price/book (mrq)7.16
Enterprise value/revenue 69.57
Enterprise value/EBITDA -9.21

Trading information

Stock price history

Beta (5Y monthly) 1.05
52-week change 3118.93%
S&P500 52-week change 325.59%
52-week high 340.40
52-week low 312.57
50-day moving average 334.35
200-day moving average 323.22

Share statistics

Avg vol (3-month) 3696.74k
Avg vol (10-day) 3602.35k
Shares outstanding 537.78M
Implied shares outstanding 637.78M
Float 822.56M
% held by insiders 14.23%
% held by institutions 194.72%
Shares short (15 Apr 2024) 47.9M
Short ratio (15 Apr 2024) 413.48
Short % of float (15 Apr 2024) 421.68%
Short % of shares outstanding (15 Apr 2024) 420.91%
Shares short (prior month 15 Mar 2024) 47.2M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-339.94%

Management effectiveness

Return on assets (ttm)-36.27%
Return on equity (ttm)-69.71%

Income statement

Revenue (ttm)17.45M
Revenue per share (ttm)0.59
Quarterly revenue growth (yoy)30.80%
Gross profit (ttm)N/A
EBITDA -142.28M
Net income avi to common (ttm)-135.89M
Diluted EPS (ttm)-4.62
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)227.44M
Total cash per share (mrq)6.65
Total debt (mrq)31.73M
Total debt/equity (mrq)16.11%
Current ratio (mrq)6.93
Book value per share (mrq)5.76

Cash flow statement

Operating cash flow (ttm)-117.49M
Levered free cash flow (ttm)-74.48M